NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment

Targher, Giovanni; Corey, Kathleen E.; Byrne, Christopher D.

doi:10.1016/j.diabet.2020.101215

Record: found
Abstract: not found
Article: not found

NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment

Author(s): Giovanni Targher , Kathleen E. Corey , Christopher D. Byrne

Publication date Created: March 2021

Publication date (Print): March 2021

Journal: Diabetes & Metabolism

Publisher: Elsevier BV

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 156

Record: found
Abstract: found
Article: not found

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Bernard Zinman, Christoph Wanner, John M. Lachin … (2015)

The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

0 comments Cited 2364 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Paul M Ridker, Brendan M. Everett, Tom Thuren … (2017)

Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.